Our Programs
Inspired by Nature. Perfected by Science. Designed for Patients.
impacting Hepatitis B Virus
nChroma’s lead program CRMA-1001 is a liver-directed epigenetic therapy being developed for chronic hepatitis B with the potential for functional cure.
With over 250 million people living with HBV, there is a significant unmet need to develop lifelong cures. By leveraging lipid nanoparticles (LNPs) to deliver the epigenetic therapy, CRMA-1001 is designed to permanently modify the chromatin structure to silence both forms of hepatitis B virus genome, cccDNA and integrated DNA.
CRMA-1001 has demonstrated significant reduction of HBV viral biomarkers in preclinical models supporting the potential to achieve functional cure in the clinic.
Targeted Silencing
Optimized epigenetic silencing constructs to achieve potent, durable, and specific silencing of HBV expression
Proven Potency
Demonstrated potential best-in-class potency in preclinical HBV models and in NHPs using a surrogate target
Advancing to Clinical Trials
Currently in CTA-enabling studies
Our Goal
Provide transformative outcomes for patients
Areas of Focus
nChroma Bio leverages innovative cargoes combined with in vivo delivery technologies enabling the flexibility to develop the optimal therapy for distinct diseases across a broad array of tissue types.
Liver
Blood
Central Nervous System
Pipeline
|
Therapeutic Area
|
Technology Applied
|
Progress Status
|
|
|---|---|---|---|
| Chronic HBV CRMA-1001 | Epigenetic Editor + LNP |
CTA-Enabling |
|
| Hematology Targeting HSPCs | Epi / Gene Editor + DLVR |
Pre-Clinical |
|
| Hematology T/B Cells | Epi / Gene Editor + DLVR |
Research |
|
| Cardiometabolic PCSK9 | Epigenetic Editor + LNP |
Candidate-Enabled |
|
| Cardiometabolic PCSK9 Multiplex | Epi / Gene Editor + LNP |
Research |
|
| CNS Various CNS Targets | Smaller Next Generation Epigenetic Editor |
Research |
Partnerships
Collaboration Fuels Discovery and Expands Possibility
Our modular in vivo delivery solutions and diverse therapeutic cargos are built to support strategic partnerships—advancing science and accelerating the development of new medicines for patients.
